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Abstract
Background: Subchronic administration of the potent pharmaceutical estrogen diethylstilbestrol (DES) to female 
Fischer 344 (F344) rats induces growth of large, hemorrhagic pituitaries that progress to tumors. Phytoestrogens 
(dietary plant estrogens) are hypothesized to be potential tumor inhibitors in tissues prone to estrogen-induced 
cancers, and have been suggested as "safer" estrogen replacements. However, it is unknown if they might themselves 
establish or exacerbate the growth of estrogen-responsive cancers, such as in pituitary.
Methods: We implanted rats with silastic capsules containing 5 mg of four different phytoestrogens - either 
coumestrol, daidzein, genistein, or trans-resveratrol, in the presence or absence of DES. We examined pituitary and 
other organ weights, blood levels of prolactin (PRL) and growth hormone (GH), body weights, and pituitary tissue 
histology.
Results: Blood level measurements of the administered phytoestrogens confirmed successful exposure of the animals 
to high levels of these compounds. By themselves, no phytoestrogen increased pituitary weights or serum PRL levels 
after 10 weeks of treatment. DES, genistein, and resveratrol increased GH levels during this time. Phytoestrogens 
neither changed any wet organ weight (uterus, ovary, cervix, liver, and kidney) after 10 weeks of treatment, nor 
reversed the adverse effects of DES on pituitaries, GH and PRL levels, or body weight gain after 8 weeks of co-treatment. 
However, they did reverse the DES-induced weight increase on the ovary and cervix. Morphometric examination of 
pituitaries revealed that treatment with DES, either alone or in combination with phytoestrogens, caused gross 
structural changes that included decreases in tissue cell density, increases in vascularity, and multiple hemorrhagic 
areas. DES, especially in combination with phytoestrogens, caused the development of larger and more 
heterogeneous nuclear sizes in pituitary.
Conclusions: High levels of phytoestrogens by themselves did not cause pituitary precancerous growth or change 
weights of other estrogen-sensitive organs, though when combined with DES, they counteracted the growth effects of 
DES on reproductive organs. In the pituitary, phytoestrogens did not reverse the effects of DES, but they did increase 
the sizes and size heterogeneity of nuclei. Therefore, phytoestrogens may oppose some but not all estrogen-
responsive tissue abnormalities caused by DES overstimulation, and appear to exacerbate DES-induced nuclear 
changes.
Background
Steroid hormones such as the dominant physiologic
estrogen, estradiol (E2) have many effects on pituitary
function, including regulation of most pituitary hor-
mones and proliferation of several pituitary cell types
[1,2]. The Fischer 344 (F344) rat has long been used as a
model for investigating growth control of estrogen-
responsive tissues (especially those prone to estrogen-
induced tumors), by various estrogens, and related bio-
logical processes such as angiogenesis [3,4]. When female
F344 rats are chronically treated with E2 or the pharma-
ceutical estrogen diethylstilbestrol (DES), their pituitaries
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grow 10 to 20 times normal size and sometimes form a
tumor by 10 weeks [5,6].
Estrogens can increase the expression levels of basic
fibroblast growth factor and pituitary tumor transform-
ing gene products in F344 animals [1,2], leading to pro-
lactinoma development, vascularization, and increases in
cell number, which have been identified as quantifiable
genetic traits [5,7].
The peptide hormone prolactin (PRL) is expressed in
the pituitary of all mammals, and its major function in
females is the stimulation of milk production by the
mammary gland. Additional known functions include
modulation of other aspects of reproduction, osmoregu-
lation, growth, metabolism, and migratory and maternal
behaviors [2]. Hyperprolactinomas release highly ele-
vated plasma PRL levels leading to reproductive dysfunc-
tion in both males and females [8,9]. There is also a tight
correlation between E2 levels and growth hormone (GH)
secretion by the pituitary. Serum GH responds to
changes in E2 levels during different life stages in women
[10,11] and regulates body growth and composition,
metabolism, bone density and pubertal development in
both sexes [12].
Phytoestrogens are plant-derived compounds that
structurally and functionally mimic mammalian endoge-
nous estrogens. These compounds have been considered
candidate therapeutic or prevention agents for such dis-
eases as reproductive system cancers, heart disease,
menopausal symptoms, and osteoporosis - essentially
mimicking the health benefits thought to be characteris-
tic of endogenous estrogens, while counteracting the haz-
ards [13,14]. Considering the numerous beneficial effects
of estrogens, it is not surprising that phytoestrogens are
considered possible complementary or alternative medi-
cine treatments. However, some estrogens are associated
with detrimental effects over life-long exposures. For
instance, cumulative high exposures to endogenous, ther-
apeutic, or environmental estrogens have been impli-
cated in diseases such as breast cancer [2,15-17].
Recently, breast cancer incidence in a large human popu-
lation was noted to be inversely correlated to the con-
s u m p t i o n  o f  s o y  p h y t o e s t r o g e n s  i n  t h e  d i e t  [ 1 8 ] .
Therefore, we need to carefully examine the beneficial vs.
the detrimental biological effects of phytoestrogens in
animal studies.
Isoflavones, including the components of soy bean-
derived foods such as genistein and daidzein, are some of
the most studied phytoestrogens. Part of the original rea-
soning behind proposing potential health benefits of phy-
toestrogens stemmed from the fact that those consuming
"Asian diets" high in soy isoflavones seem to be less vul-
nerable to the diseases of both estrogen overexposure
(cancers) and estrogen underexposure (osteoporosis, hot
flashes, heart disease, depression, etc.). These benefits are
thought to be diet-related rather than genetic, because
when Asians move to Western countries and adopt their
diets, their incidences of these diseases become similar to
Westerners [19,20]. Coumestrol which is supplied by
foods such as alfalfa sprouts, or is transmitted to the diet
via red clover consumption by livestock, is also thought
to have these beneficial effects. Resveratrol consumption,
also speculated to be beneficial, could explain why popu-
lations that daily consume red wine (which contains high
levels of resveratrol) benefit by having lower levels of dis-
eases thought to be associated with estrogen deficits (eg.
heart disease).
The different activities and the bioavailability of phy-
toestrogens vary depending on factors such as the route
of administration, dosage, individual metabolism, co-
ingestion of other substances, and phytoestrogen levels
present in intake foods [21,22]. For example, in Japanese
men and women consuming a traditional diet, the plasma
isoflavone concentrations can be as high as 0.2 to 1 μM.
In Europe and North America, plasma concentrations for
isoflavones are between 0.005 and 0.4 μM [22-24]. The
blood concentrations for coumesterol can be from 0.01
(reported as an average from food intake, Malaysia [25])
to 0.5 μM (resulting from taking dietary supplements
[24]). Resveratrol, a compound which has very low bio-
availability and is rapidly metabolized in humans [26,27],
has serum concentrations (for the compound and its
metabolites) as high as 2 μM [28]. In the present studies,
these four phytoestrogens were provided via sustained
slow release directly to the circulation, bypassing gut
microflora and hepatic first pass metabolism, which can
have a major impact on the biological potency of phytoe-
strogens. We examined estrogenic effects on size and
architecture of multiple organs (both reproductive and
not), and on body weights, in female F344 rats. In partic-
ular we focused on the size, structure, cellular composi-
tion, and function of the pituitaries, as this tissue is used
to monitor carcinogenic estrogenic effects in this animal
model. Our studies investigate whether phytoestrogens
mimic, inhibit, or exacerbate the known effects of DES.
Methods
Cholesterol, flavone, DES, trans-resveratrol, coumesterol,
daidzein, and genistein were obtained from Fluka (Mil-
waukee, WI) or Sigma Chemical Co. (St. Louis, MO). The
high purity grade solvents and silica gel were purchased
from Fisher Scientific (Pittsburgh, PA).
Animals and hormone treatment
There are several issues which often arise in dietary treat-
ment regimens for phytoestrogens. The rationale for our
protocol limits animal use and manipulations, while still
addressing important issues of comparisons of phytoe-
strogen modulation of estrogenic carcinogenesis. WeJeng et al. Nutrition & Metabolism 2010, 7:40
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used a high level of phytoestrogen exposure to determine
if any harm could be caused by this exposure. Since these
doses of phytoestrogens far exceed that which could be
delivered by the animal feed (demonstrated by the blood
levels of free compounds in our control animals being
undetectable), we thought it unnecessary to feed a spe-
cialized diet to eliminate such a comparatively negligible
source of phytoestrogens. Because we did not know
whether simultaneous phytoestrogen exposure would
inhibit or exacerbate tumor development, we used a sub-
end point tumor development assessment time in ani-
mals receiving DES in combination with phytoestrogens.
Were phytoestrogens to exacerbate tumor growth, then
the animals might not survive for the entire 10 week
induction period. We chose an 8 week endpoint which
had been shown to still generate DES-induced growth
effects, but to a less developed stage [29]. On the other
hand, if any phytoestrogens alone were to have less of an
effect on pituitary growth than DES, we reasoned that
these effects would be difficult to observe at shorter
exposure times. Therefore, we used the full 10 week time
point for this outcome. Because we were using very high
doses of DES (tumor induction levels) and phytoestro-
gens, the reproductive cycles of these animals would be
overwhelmed with the effects of administered estrogens
that have been shown to disrupt estrous cycles [30,31].
Also, the high doses used in these studies rendered the
contribution of endogenous estrogens very minor, so we
did not ovariectomize the test animals.
Female F344 rats (21 days old) were obtained from Har-
lan Sprague-Dawley (Indianapolis, IN) and housed (five
rats per cage) in a controlled environment (light on, 0500-
1900 hours, 22°C, and 50% humidity) with free access to
water and food (Prolab RMH 2500 LabDiet, Richmond,
IN). For implanting hormone-containing capsules, rats
were anesthetized, followed by 5 mm neck incisions and
subcutaneous placement of pieces of silastic tubing
(Allied Biomedical, Paso Robles, CA). Animals were
treated for 10 weeks with implants containing 5 mg of
cholesterol (negative control), DES (positive control),
coumesterol, daidzein, genistein, or trans-resveratrol
(Sigma, St. Louis, MO). To investigate whether phytoe-
strogens inhibit or exacerbate the known effects of DES
exposure in this paradigm (growth of pituitary and pitu-
itary tumors), another set of animals received subcutane-
ous silastic implants containing 5 mg DES along with 5
mg of either cholesterol, coumesterol, daidzein, genistein,
or trans-resveratrol for 8 weeks. There were 10 rats per
group and animals were weighed weekly. Blood was col-
lected from each animal into centrifuge tubes that con-
tained no anti-coagulant at 4 weeks and at sacrifice for
analysis of PRL and GH levels. To confirm successful
release of phytohormones and DES by the implants, the
collected blood from rats treated with single compounds
was also assayed for free phytoestrogens or DES. Plasma
was separated according to standard protocol and the
samples aliquoted and stored at -80°C until analysis. Pitu-
itaries, estrogen-sensitive reproductive organs (cervices,
ovaries, uteri) and non-reproductive organs (kidneys and
livers) were carefully dissected from surrounding tissues
and weighed. Pituitaries were fixed in 4% PBS-buffered
paraformaldehyde, followed by imbedding, sectioning (5
μm) and staining with hematoxylin and eosin [32]. This
use of animals was approved by the Institutional Animal
Care and Use Committee at UTMB.
Extraction and analysis of phytoestrogens in the plasma
Flavone (1 ng, internal standard) was added to the rat
plasma (250 μL) and incubated at 37°C for 30 min fol-
lowed by an addition of 0.1 ml acetic acid and 2 mL meth-
anol:diethylether (3:1, v/v). The contents were mixed well
and sonicated for 2 min, then centrifuged at 600 × g for
15 minutes. Supernatants were transferred into clean
glass vials and solvent was evaporated under a stream of
nitrogen at 40°C. The residue was redissolved in 1 ml n-
heptane and subjected to silica gel solid-phase extraction.
The silica gel column was washed with 3 mL methanol
followed by 3 mL n-heptane. The sample was loaded onto
the silica gel column and then washed with 10 mL n-hep-
tane. Elution was done by adding 5 mL methanol. The
eluate was evaporated under nitrogen and redissolved in
200 μL of mobile phase A (23:24:53 acetonitrile: metha-
nol: water) and analyzed by high performance liquid
chromatography (HPLC).
Analysis of individual phytoestrogens was carried out
on a Beckman Coulter System Gold (Pump module 125,
PDA Detector 168, and manual injector). Data acquisi-
tion and post-run analysis were performed using 32Karat
v7.0 combined with Gemini ODS [length 250 mm, parti-
cle size 5 μm, I.D. 4.6 mm, Phenomenex (Torrance, CA)].
Elution was done by acetonitrile: methanol: water
(23:24:53, v/v) containing 0.01% trifluoro acetic acid flow-
ing at 0.7 ml/min under isocratic conditions. The detec-
tor was set at 254 nm for DES, coumesterol daidzein, and
genistein [33] and 306 nm for trans-resveratrol [34]. A
minimum of 5 pmol of each compound was detectable by
the method used in this study. Recovery of phytoestro-
gens was found to be > 90%. The data were corrected for
the percent recovery.
Assay of serum PRL and GH
The serum levels of PRL and GH were measured using an
enzyme immunoassay kit from Alpco (Windham, NH)
and Millipore (Billerica, MA) respectively, according to
the manufacturer's instructions.
Nuclear morphometry of the pituitary
Representative sections were analyzed using a Nikon
Eclipse E800-UIC upright microscope equipped with aJeng et al. Nutrition & Metabolism 2010, 7:40
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Nikon digital DXM 1200 color CCD camera and PL FL
10× objective (N.A. 0.3) controlled by ACT-1 acquisition
software (Nikon, Melville, NY). Representative images (2-
4) were acquired from each rat anterior pituitary.
Acquired digital images were processed with Metamorph
7.0 software (Molecular Imaging, Downingtown, PA)
using manual outlining of nuclear images for subsequent
measurement of nuclear areas. Nuclei (80-200) were ran-
domly selected from each image and measured. Results
were averaged to obtain the mean nuclear size for each
pituitary and then combined to plot a histogram. To com-
pare different treatments, the average of the mean
nuclear size from each individual animal's tissue was
used.
Statistics
Data from the morphometrics analysis of pituitary tissue,
organ weights, serum PRL and GH levels, and serum con-
centrations of phytoestrogens were analyzed by one-way
analysis of variance (ANOVA) followed by multiple com-
parisons versus control group (Holm-Sidak method). The
Sigma Stat 3 program (Systat Software, Inc.) was used for
all statistical analysis, and significance was accepted at p
< 0.05.
Results
Serum levels of phytoestrogens after 4 and 10 weeks of 
treatment
To show the effectiveness of our silastic implant delivery
system, we measured serum levels for DES and all phy-
toestrogens in F344 animals after 4 and 10 weeks of treat-
ment (Table 1). All compounds were readily detectable in
serum at both time points, and were near the higher end
of those values obtained via dietary exposure reported for
both rodents and humans. The serum levels of DES,
coumesterol, and genistein were higher in blood collected
after 10 weeks compared to 4 weeks of treatment, but res-
veratrol levels were highest after only 4 weeks. Neither
daidzein nor trans-resveratrol treatments resulted in fur-
ther increases in the amounts of the compounds in blood
at 10 weeks. No detectable levels of these phytoestrogens
were found in control animals whose implants contained
cholesterol.
Effects of phytoestrogens on pituitary weights, PRL levels, 
GH levels, and body weights (Figure 1)
Pituitaries were greatly increased in size after 10 weeks
treatment with DES. As previously reported for this
experimental model, the weight increase was ~10-fold
compared to control animals. In DES-treated animals,
the serum PRL levels were elevated ~6-fold, and the GH
levels were elevated ~9-fold. The body weights of DES-
treated animals were significantly lower than control ani-
mals. None of the four different phytoestrogen treat-
ments altered the pituitary weights, PRL levels, or body
weights of these F344 rats. However, among the phytoe-
strogens, both genistein and resveratrol caused a 6-fold
increase in GH levels.
Effects of phytoestrogens on reproductive and 
nonreproductive organ weights (Figure 2)
W e  a l s o  e x a m i n e d  t h e  w e t  w e i g h t  o f  s e v e r a l  o r g a n s
from animals exposed to these various estrogen implants
for 10 weeks. DES treatment increased wet weights of
reproductive organs (ovaries, uteri, and cervices) at 10
weeks, as expected. However, none of the phytoestrogens
Table 1: Serum concentrations of phytoestrogens
Treatment 4th week 10th week Reported rat serum concentrations (ng/ml)
DES 20 ± 5 ng/ml 353 ± 60 ng/ml For comparison, serum E2 levels in cycling
(0.07 ± 0.02 μM) (1.3 ± 0.2 μM) F344 rats is 1-16 pg/ml (4-59 pM) [54]
Coumesterol 182 ± 18 ng/ml 590 ± 83 ng/ml ND-10 ng/ml (0.04 μM) [52]
(0.68 ± 0.07 μM) (2.2 ± 0.31 μM)
Daidzein 30 ± 2 ng/ml 43 ± 5 ng/ml ND-13 ng/ml (0.05 μM) [52]
(0.12 ± 0.07 μM) (0.17 ± 0.02 μM)
Genistein 14 ± 5 ng/ml 117 ± 12 ng/ml ND-28 ng/ml (0.10 μM) [52]
(0.05 ± 0.02 μM) (0.43 ± 0.04 μM)
Trans-resveratrol 58 ± 15 ng/ml 49 ± 9 ng/ml ND [27,55]
(0.25 ± 0.06 μM) (0.21 ± 0.04 μM)
Free phytoestrogens in blood from animals with implants for 4 or 10 weeks (n = 10 animals per group) are shown in both ng/ml and molar 
concentrations. Five blood samples from each group were analyzed. The control animals (with cholesterol implants) had below detectable 
levels for all measured compounds. The last column lists referenced phytoestrogen levels in rat serum from untreated rats. ND = 
nondetectable.Jeng et al. Nutrition & Metabolism 2010, 7:40
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had any significant effects on reproductive organs (Figure
2A-C). The weights of livers and kidneys were not signifi-
cantly affected by either DES or any of the tested phytoe-
strogens (Figure 2D-E).
Effects of combinations of DES and phytoestrogens on 
pituitary weights, PRL levels, GH levels, and body weights 
(Figure 3)
Pituitary weights increased significantly (~3 fold) after
8 weeks of treatment with DES, as expected for this non-
linear tumor development model system [3], whether or
not the phytoestrogens were co-administered; therefore,
no phytoestrogen treatment significantly changed the
size progression of DES-treated pituitaries, in either a
positive or negative direction. Serum PRL and GH levels
were also significantly elevated in animals treated with
DES alone; again, co-treatment with phytoestrogens did
not alter this elevation. Essentially, the pituitary weight
effects were reflected in the similar increases in PRL lev-
els. The body weights were significantly (25%) lower in
DES-treated animals, regardless of whether it was admin-
istered with or without any of the phytoestrogens. There-
fore, phytoestrogen treatment did not significantly
change the estrogenic effects of DES.
Effects of combinations of DES and phytoestrogens on 
reproductive and nonreproductive organ weights (Figure 
4)
We also examined the reproductive organs of F344 rats
co-treated with DES and different phytoestrogens (Figure
4A-C). Interestingly, DES did not increase the size of the
uterus in these studies of only 8 weeks of DES exposure
(even though the 10 week exposure did cause this effect,
see Figure 2). Yet in the same animals, ovary and cervix
weights were increased by this 8 week treatment, so it is
apparent that the animals were exposed to an effective
dose of DES. All phytoestrogens attenuated the effects of
DES size gain in ovaries and cervices. The weights of liv-
Figure 1 Pituitary weight and functions, and body weight in animals treated with DES or phytoestrogens. A. wet pituitary weights; B. serum 
PRL levels; C. serum GH levels; and D. body weights of animals treated with DES (diethylstibesterol), Cou (coumesterol), Dai (daidzein), Gen (genistein), 
or Resv (trans-resveratrol) for 10 weeks. * = p < 0.05 compared to control animals treated with cholesterol (Chol) only. n = 10 animals for each group.
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ers and kidneys were not affected by DES alone or in
combination with any of the tested phytoestrogens (Fig-
ure 4D-E), similar to those results obtained at 10 weeks
with single compounds (see Figure 2).
Nuclear changes in anterior pituitary induced by 
phytoestrogens and DES
DES treatment, either alone or in combination with phy-
toestrogens, caused gross structural changes in rat ante-
rior pituitaries that included decrease in cell density in
the tissue, increase in vascularity, and multiple areas of
hemorrhages (representative pictures shown in Figure 5).
To investigate whether there were any other quantifiable
microscopic changes, we also examined the nuclear sizes
of pituitary cells from each animal (Figure 6) using soft-
ware-assisted micromorphotometric techniques.
Although none of the phytoestrogens alone produced sig-
nificant changes in this parameter, combinations of daid-
zein, genistein, or resveratrol with DES treatment
resulted in significantly larger nuclear areas compared to
control or DES alone treatment groups. [Although the
coumestrol + DES treatment group was not significantly
different from treatment with either of the single com-
pounds alone, the differences approached significance (P
= 0.139 compared to DES and 0.129 for coumestrol)]. As
seen in the histogram of nuclear sizes (Figure 7), this
Figure 2 DES- or phytoestrogen-induced wet organ weights. The wet weight of organs from animals treated with DES, Cou, Dai, Gen, and Resv 
for 10 weeks including A. uterus; B. ovary; C. cervix; D. kidney; and E. liver. The abbreviations are as defined in the legend of Figure 1. * = p < 0.05 com-
pared to control (Chol) animals. n = 10 animals for each group.
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observed increase in average nuclear area was accompa-
nied by a marked increase in nuclear size polymorphism
(multiple peaks in the nuclear size histogram) as well as
multiple giant nuclei, especially in the DES + phytoestro-
gens treatment groups. In each case, treatment with DES
plus a phytoestrogen broadened the profile in the direc-
tion of larger and more heterogenously-sized nuclei. This
is quantified in Table 2 which shows the % of cells that
have a nuclear area of a > 800 value for ranked nuclear
size.
Discussion
These studies examined organ size and functional
responses to several phytoestrogens, in comparison to
the actions of a well-studied pharmaceutical estrogen-
induced model for carcinogenicity. The stimulatory
effects of DES treatment on pituitary function were
robust (as expected for this well established model) in
these young (21 day old) female F344 rats treated with
estrogens for ~2 months. Large impacts on pituitary
functions and reproductive maturation was expected in
animals whose human life-span equivalency approxi-
mated the beginning of puberty. DES treatment increased
the size, as well as caused structural changes, in the pitu-
itary. However, phytoestrogen treatments, even at these
high concentrations, neither caused the same effects, nor
attenuated the effects of DES. DES treatment also
increased serum PRL and GH levels, and two phytoestro-
gens, genistein and resveratrol, also caused significant
increases in serum GH levels. Genistein was previously
reported to increase GH in ewes and rats [35,36]. These
kinds of effects may be related to estrogenic effects on
stature in both boys and girls [37]. Although daidzein is
very similar in chemical structure to genistein, it did not
increase the serum GH levels. This may be due to the
lower serum daidzein levels at 10 weeks compared to
Figure 3 Pituitary weight and functions, and body weight in animals treated with DES + phytoestrogens. A. The wet weights of pituitaries; B. 
serum PRL levels; C. serum GH levels; and D. body weight, from animals treated without (open bar) or with DES (dark bars) in combination with Chol 
(control), Cou, Dai, Gen, and Resv for 8 weeks. The abbreviations are as defined in the legend of Figure 1. * = p < 0.05 compared to control (Chol) 
animals without DES treatment. n = 10 animals for each group. There were no statistically significant differences between animals treated with DES 
alone, compared to DES + phytoestrogens.
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genistein, or to the broader signaling capabilities of
genistein (for instance to also inhibit tyrosine kinases
[36]). These effects are clearly separable from the effects
on pituitary weight in our study, as no phytoestrogens
were able to change the pituitary weights. Known effects
of GH and PRL do not explain the phytoestrogen-
induced reversal of DES-induced growth on the cervix
and ovary that we observed. However, as we have shown
previously in pituitary tumor cell lines, some of the abili-
ties of phytoestrogens to change tissue growth patterns
could be related to their capacity to differentially activate
caspases and several mitogen-activated protein kinases
[38,39] via nongenomic signaling mechanisms.
Figure 4 Wet organ weights as affected by DES treatment in combination with phytoestrogens. The weight of reproductive organs including: 
A. uterus; B. ovary; C. cervix; and non-reproductive organs: D. kidney; and E. liver, from animals treated without (open bar) or with DES (dark bars) in 
combination with Chol (control), Cou, Dai, Gen, and Resv for 8 weeks. The abbreviations are as defined in the legend of Figure 1. * = p < 0.05 compared 
to control (Chol) animals without DES treatment. # = p < 0.05 vs. DES alone. n = 10 animals for each group.
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The average nuclear size in pituitary cells (which
reflects their functional state) is known to be changed
due to perturbations in hormonal status [40-42].
Although the average nuclear size from pituitaries of
DES-treated or phytoestrogen-treated animals showed
no difference compared to cholesterol-treated control
animals, the observed changes in nuclear size heteroge-
neity with DES (and especially with DES in combination
with all phytoestrogens), suggested that the functions of
pituitary cells had been altered. High serum PRL and GH
levels as well as pituitary size increases in animals treated
with DES suggest that nuclear heterogeneity can be a
marker for peptide hormone production and/or growth
i n  t h e  p i t u i t a r y ,  t h o u g h  e l e v a t e d  G H  l e v e l s  c a u s e d  b y
genistein did not correlate with such nuclear changes. It
is interesting that phytoestrogens increased nuclear area
o n l y  w h e n  t h e i r  a c t i o n s  w e r e  s u p e r i m p o s e d  o n  D E S
effects, and that the corresponding serum PRL and GH
levels did not reflect any additional changes due to these
combinations. Increases in nuclear size measured by tis-
sue morphometry have been previously correlated to
high risk pre-invasive breast lesions [43], and pituitary
tumors are known to have large pleiomorphic nuclei [44].
Estrogens have also been shown recently to alter nuclear
morphology related to MAPK activation and changes in
cell division machinery [45]. Though the nuclear size
changes we observed are not directly connected to a
known health risk, they could signal some tissue growth
instabilities brought on by excessive and diverse estro-
genic exposure which would require more exposure time
to manifest their effects. However, the levels of exposure
that we examined were very high and were intended to
Table 2: Combinations of DES and phytoestrogens increase the % of cells that have large nuclear size.
Treatment % cells > 800
Without DES
% cells > 800
With DES
Cholesterol 1.67 3.71
Coumesterol 1.97 8.94
Daidzein 0.80 30.17
Genistein 0.24 16.35
Trans-resveratrol 3.13 23.49
The percent of cells with nuclei areas above the 800 value for ranked nuclear size (see Figure. 7) is shown.
Figure 5 Representative stained pituitary tissues from animals 
treated with DES, daidzein, or the combination: The hematoxylin 
and eosin staining of pituitary tissues were recorded at 400× magnifi-
cation from animals treated with A. cholesterol; B. DES; C. daidzein; or 
D. daidzein + DES. Note the large vascular and hemorrhagic areas 
(black arrows in B and D) resulting from DES treatments, regardless of 
whether daidzein (or other phytoestrogens) were administered in 
combination. Also note the larger nuclear size in animals treated with 
daidzein + DES (blue arrowheads in D). Combination treatments with 
DES plus other phytoestrogens gave similar results.
Figure 6 Nuclear morphometric changes in rat anterior pituitar-
ies induced by phytoestrogens, DES, or combination treatments. 
Average nuclear areas were estimated as described in methods (n = 4-
8 animals for each treatment group), * = p < 0.05 vs. control (Chol), # = 
p < 0.05 vs. DES alone.
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Figure 7 Nuclear size histogram of pituitary cells: Individual nuclei (n = 1200-3000 for each group) measurements for anterior pituitaries were plot-
ted as the 100-bin histogram, reflecting their variability and distribution by size. The Y axis shows the number of nuclei counted and X-axis shows the 
ranked nuclear size. See table 2 for the percentages of cells with large nuclear sizes (> 800).
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demonstrate actions in an experimental situation where
DES was known to cause pituitary tumorigenesis over a
short time period.
Our use of this animal model for carcinogenesis dem-
onstrated the expected estrogenic overstimulation by
DES on the reproductive organs of female F344 rats. Oth-
ers have reported that estradiol or DES treatment
increases uterine wet weight, epithelial thickness, loose
density stroma, and development of more uterine glands
[46]. They also regulate cervical epithelial cell prolifera-
tion [47] and increases ovarian wet weight [48], including
in F344 rats. However, phytoestrogens by themselves had
none of these effects at the organ weight level, though
they were able to suppress the weight gain effects of DES
in ovaries and cervices after 8 weeks of co-treatment. So
where reproductive organs show estrogenic effects, phy-
toestrogens may be an effective foil.
Only DES caused lower body weights in our study,
which could not be reversed by phytoestrogens. Sex hor-
mones are known to regulate rat body weights [49]; possi-
ble mechanisms include decreased metabolism and
decrease lipoprotein lipase activity in adipose tissues [50].
Other studies have suggested that estrogens, especially at
high concentrations, can cause nausea, indirectly contrib-
uting to poor eating and weight loss, which could con-
tribute to the prevalence of anorexia in adolescent girls
[51]. None of the high dose phytoestrogens in our study
caused weight loss effects similar to DES, at least not for
such subchronic exposures.
There is a concern that phytoestrogens present in ani-
mal feeds may affect experimental outcomes and also
cause phytoestrogen exposures to humans consuming
livestock fed on such diets [19,21]. Blood phytoestrogen
content in our control animals was not detectable, and if
present, negligible compared to the high concentrations
delivered by our implants. The fact that the levels of these
compounds were undetectable in the cholesterol-fed con-
trol animals using our sensitive extraction and assay
methods, correlates with the amounts attributable to ani-
mal feed previously studied [52].
The increase in serum levels of coumesterol, daidzein,
and genistein from 4 to 10 weeks suggests bioaccumula-
tion, as has been suggested by previous studies [53].
Though factors such as species, age, developmental sta-
tus, gender, diet, dose, route of administration, and
metabolism all influence the ultimate phytoestrogen
exposure, limiting the effectiveness of comparisons
between studies in both rodents and humans, the levels of
serum phytoestrogens that we report are comparable to
high human levels. It appears that even such high doses of
phytoestrogens did not cause effects in the organs or hor-
monal systems that we examined, except to alter some
microscopic tissue architecture when in combination
with a carcinogenic estrogen (DES). However, with some
exceptions on reproductive organs, neither did they
counteract the effects of this known potent estrogenic
carcinogen.
Conclusions
Our studies demonstrated that phytoestrogens by them-
selves, even in very high subchronic doses (that could
match, however, accumulations in human blood via
dietary intake [22-25,28]), did not cause the growth of
pituitaries to sizes associated with tumor development,
nor did they cause the growth of other reproductive, non-
reproductive, or xenoestrogen-processing metabolic
organs (liver or kidney). Though the phytoestrogens were
unable to attenuate the effects of DES treatment on PRL
and GH levels, pituitary weight, and body weight, they
were able to reverse the DES-induced reproductive organ
weight gains. So, it is these effects which may contribute
to any protection such estrogens may give from endoge-
nous or environmental estrogen overexposure. Concerns
that have been raised about safety of these compounds as
dietary supplements are not supported by many of our
results, though the carcinogenic estrogen + phytoestro-
gen effects that we showed on nuclear size and heteroge-
neity should be studied further.
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